Form 4: Immunovant Executive Sells Shares to Cover Tax Obligations

Jay S. Stout, Chief Technology Officer of Immunovant, Inc., sold 5,004 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On April 9, 2025, Jay S. Stout, the Chief Technology Officer of Immunovant, Inc., sold 5,004 shares of Immunovant common stock.
• The shares were sold at a weighted average price of $12.99 per share, with individual transactions ranging from $12.75 to $13.26.
• The sale was mandated by Immunovant to cover tax withholding obligations associated with the vesting of 13,744 restricted stock units (RSUs) that vested on April 2, 2025.
• Following the transaction, Stout still beneficially owns 211,168 shares of Immunovant common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transaction is a routine sale to cover tax obligations and doesn't reflect a change in the executive's overall confidence in the company.

Industry Context

Executive stock sales are a common occurrence, particularly to cover tax obligations related to equity compensation. The sale itself doesn't necessarily indicate a negative outlook for the company.

Stakeholder Impact

• The sale has a minimal impact on shareholders as it is a small percentage of the total outstanding shares and is related to tax obligations.

Key Dates

Keywords

Immunovant, IMVT, Jay S. Stout, Chief Technology Officer, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding, Beneficial Ownership